Core Viewpoint - Henry Schein, Inc. (HSIC) reported adjusted earnings per share (EPS) of $1.15 for Q1 2025, reflecting a 4.5% increase year-over-year and exceeding the Zacks Consensus Estimate by 3.6% [1][12] Financial Performance - The company recorded a GAAP EPS of 88 cents, up from 72 cents in the same quarter last year [2] - Q1 revenues were $3.17 billion, a slight decline of 0.1% year-over-year, and fell short of the Zacks Consensus Estimate by 1.8% [3] - Constant currency total net sales increased by 1.4%, while excluding PPE and COVID-19 test kits, sales growth was 2% year-over-year [3] Segment Analysis - Global Distribution and Value-Added Services segment sales decreased by 0.7% to $2.68 billion, with a 0.8% increase in constant currencies [4] - Global Dental Distribution merchandise sales rose by 0.4% in constant currencies, while equipment sales fell by 2.4% due to sales deferrals [5] - Global Medical Distribution sales increased by 3% in constant currencies, driven by higher patient traffic and growth from acquisitions [5] - Global Specialty Products segment sales totaled $367 million, up 2% on a reported basis [6] - Global Technology segment sales reached $162 million, reflecting a 2.9% increase on a reported basis [7] Margin and Liquidity - Gross profit for the quarter was $1.00 billion, a 1.2% decrease year-over-year, with gross margin contracting to 31.6% [8] - SG&A expenses decreased by 6.7% to $738 million, while adjusted operating profit rose by 18.6% to $262 million [8] - The company ended Q1 2025 with cash and cash equivalents of $127 million, up from $122 million at the end of Q4 2024 [9] Share Repurchase and Guidance - HSIC repurchased approximately 2.3 million shares at an average price of $71.58, totaling around $161 million, with $718 million available for future repurchases [10] - The company maintained its adjusted EPS forecast for 2025 in the range of $4.80-$4.94, indicating 1-4% growth from 2024 [11] Strategic Outlook - HSIC is advancing its BOLD+1 Strategic Plan for 2025 to 2027, focusing on operational efficiency, enhancing customer experience, and expanding its digital solutions [13]

Financial Data and Key Metrics Changes - Global sales for the first quarter of 2025 were $3.2 billion, down 0.1% compared to the first quarter of 2024, with a 1.5% decrease attributed to foreign currency exchange and a 1.2% growth from acquisitions [27][28] - GAAP operating margin improved by 81 basis points to 5.53%, while non-GAAP operating margin increased by 14 basis points to 7.25% [28] - GAAP net income for the first quarter was $110 million or $0.88 per diluted share, compared to $93 million or $0.72 per diluted share in the prior year [28] - Non-GAAP net income was $143 million or $1.15 per diluted share, compared to $143 million or $1.10 per diluted share in the prior year [29] Business Line Data and Key Metrics Changes - U.S. Dental merchandise sales grew low single digits, while U.S. Dental equipment sales declined by 8.9% due to a deferral of approximately $20 million in sales from Q4 2023 to Q1 2024 [30][31] - U.S. Medical distribution sales grew by 4.7% after excluding PPE products and COVID test kits, with Home Solutions business experiencing a total sales growth of 23% [32] - Global Specialty Products Group saw constant currency sales growth of 4.3%, benefiting from acquisition growth primarily from TriMed [33] Market Data and Key Metrics Changes - International Dental merchandise constant currency sales grew by 1.1%, while international Dental equipment constant currency sales grew by 4.3%, driven by strong growth in Canada and Central Europe [32][33] - The U.S. implant market was slightly down in Q1 2025, with strong sales growth in the DACH region and Latin America [20][21] Company Strategy and Development Direction - The company is advancing its Bold Plus One strategic plan, focusing on growing the distribution business, enhancing customer experience, and developing digital solutions [10][11] - The establishment of two main business units: Global Distribution and Value Added Service Group, and Global Technology Group, is aimed at improving operational efficiency [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the fundamentals of the business, noting good sales performance in February and March following a slow January due to weather-related events [8][10] - The company expects to achieve high single-digit to low double-digit earnings growth by executing its strategic plan [10] Other Important Information - The company repurchased approximately 2.3 million shares of common stock during the first quarter at an average price of $71.58 per share, totaling $161 million [35] - The company is maintaining its 2025 financial guidance, expecting non-GAAP diluted EPS to be in the range of $4.80 to $4.94 [38] Q&A Session All Questions and Answers Question: Can you talk about the dollar's impact on revenue guidance? - The company experienced a headwind of about 1.5% from foreign exchange in Q1, but expects foreign exchange to be largely neutral for the remainder of the year [44][45] Question: Can you provide clarity on the operating environment and April's performance? - April was a decent month, with stable traffic for Dental distribution businesses and increased patient traffic for medical sales [47][50] Question: Are there any adjustments to your guidance inputs? - The sales guidance remains consistent, with most growth expected to be internally generated [55] Question: Can you comment on the tariff impacts? - The company is confident in mitigating the financial impact of tariffs through various strategies, including sourcing from lower tariff countries [56][58] Question: How is the dental capital equipment environment? - There has been healthy demand for equipment orders, with no significant adverse reactions noted [108] Question: What is the current sentiment among DSOs? - DSOs are stable to leaning positively, with many adjusting to higher interest rates and continuing to invest in expansion [115]

Group 1: Earnings Performance - Henry Schein reported quarterly earnings of $1.15 per share, exceeding the Zacks Consensus Estimate of $1.11 per share, and showing an increase from $1.10 per share a year ago, representing an earnings surprise of 3.60% [1] - The company posted revenues of $3.17 billion for the quarter ended March 2025, which missed the Zacks Consensus Estimate by 1.84%, remaining unchanged from year-ago revenues [2] Group 2: Stock Performance and Outlook - Henry Schein shares have declined approximately 5.6% since the beginning of the year, compared to a decline of 3.3% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $1.18 on revenues of $3.22 billion, and for the current fiscal year, it is $4.82 on revenues of $12.99 billion [7] Group 3: Industry Context - The Medical - Dental Supplies industry, to which Henry Schein belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Financial Data and Key Metrics Changes - Global sales for the first quarter of 2025 were $3.2 billion, down 0.1% compared to the first quarter of 2024, with a 1.5% decrease due to foreign currency exchange and a 1.2% growth from acquisitions [26][27] - GAAP operating margin improved by 81 basis points to 5.53%, while non-GAAP operating margin increased by 14 basis points to 7.25% [27] - GAAP net income for the first quarter was $110 million or $0.88 per diluted share, compared to $93 million or $0.72 per diluted share in the prior year [27] - Non-GAAP net income was $143 million or $1.15 per diluted share, compared to $143 million or $1.10 per diluted share in the prior year [28] Business Line Data and Key Metrics Changes - U.S. Dental merchandise sales grew low single digits, while U.S. Dental equipment sales declined 8.9% due to a deferral of approximately $20 million in sales from Q4 2023 to Q1 2024 [30][31] - U.S. Medical distribution sales grew by 4.7% after excluding PPE products and COVID test kits, with Home Solutions business experiencing a total sales growth of 23% [31][32] - Global Specialty Products Group saw constant currency sales growth of 4.3%, with strong growth in the DACH region and Latin America [32][33] Market Data and Key Metrics Changes - International Dental merchandise sales grew 1.1% in constant currency, while international Dental equipment sales grew 4.3% driven by strong growth in Canada and Central Europe [32] - The U.S. implant market was slightly down, but the company maintained market share and saw strong sales growth in Europe, particularly in Germany [21][33] Company Strategy and Development Direction - The company is advancing its Bold plus One strategic plan, focusing on operational efficiency, enhancing customer experience, and growing its digital footprint [9][10] - The establishment of two main business units, the Global Distribution and Value Added Service Group and the Global Technology Group, aims to streamline operations and improve performance [9][10] - The company expects high single-digit to low double-digit earnings growth by executing its strategic initiatives [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the fundamentals of the business despite a slow start in January due to weather-related events, with sales performance improving in February and March [6][8] - The overall mood in the dental and medical markets is stable, with increased patient traffic and investment in practices [50][62] - Management acknowledged the potential impact of tariffs but believes current actions will mitigate financial effects [24][58] Other Important Information - The company repurchased approximately 2.3 million shares at an average price of $71.58 per share, totaling $161 million [34] - The company maintains its 2025 financial guidance, expecting non-GAAP diluted EPS in the range of $4.80 to $4.94 [38] Q&A Session Summary Question: Can you talk about the dollar's impact on revenue guidance? - The company experienced a 1.5% headwind from foreign exchange in Q1, but expects foreign exchange to be neutral for the remainder of the year [44][45] Question: What is the current environment in April? - April showed decent performance, with stable traffic in dental distribution and solid growth in medical sales due to increased patient visits [47][50] Question: Are there any adjustments to guidance inputs? - The company maintains its sales guidance, expecting growth to be largely internally generated with foreign exchange being neutral [56] Question: How is the company managing tariff impacts? - The company is diversifying sourcing to mitigate tariff impacts and is working closely with suppliers and customers [58][59] Question: What is the current state of the dental capital equipment market? - Demand for dental equipment remains healthy, with no significant declines in orders observed [109]

1 Cautionary Note Regarding Forward-Looking Statements and Use of Non-GAAP Financial Information Q1 2025 Earnings Conference Call In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. Financial Results & Outlook All forward-lo ...

Financial Performance - First-quarter 2025 GAAP diluted EPS was $0.88, a growth of 22% compared to Q1 2024[6] - First-quarter 2025 non-GAAP diluted EPS was $1.15, reflecting a growth of 4.5% compared to Q1 2024[6] - Total net sales for Q1 2025 were $3.2 billion, with constant currency sales growth of 1.4% compared to Q1 2024[7] - Global Medical Distribution sales increased by 3.0% in constant currencies compared to Q1 2024, with as-reported sales up by 2.9%[12] - Global Specialty Products sales grew by 4.3% in constant currencies compared to Q1 2024, with as-reported sales increasing by 2.0%[12] - Net sales for Q1 2025 were $3,168 million, a slight decrease of 0.1% compared to $3,172 million in Q1 2024[32] - Gross profit for Q1 2025 was $1,000 million, down from $1,012 million in Q1 2024, reflecting a gross margin of 31.5%[32] - Operating income increased to $175 million in Q1 2025, compared to $150 million in Q1 2024, representing a growth of 16.7%[32] - Net income attributable to Henry Schein, Inc. rose to $110 million in Q1 2025, up from $93 million in Q1 2024, marking an increase of 18.3%[32] - Basic earnings per share increased to $0.89 in Q1 2025, compared to $0.72 in Q1 2024, reflecting a growth of 23.6%[32] - Net income attributable to Henry Schein, Inc. for Q1 2025 was $110 million, representing a 17.7% increase from $93 million in Q1 2024[42] - Diluted EPS attributable to Henry Schein, Inc. increased by 22.2% to $0.88 in Q1 2025, up from $0.72 in Q1 2024[42] - Non-GAAP net income attributable to Henry Schein, Inc. remained stable at $143 million, with a slight increase of 0.5% compared to Q1 2024[42] - Non-GAAP diluted EPS attributable to Henry Schein, Inc. rose by 4.5% to $1.15 in Q1 2025, compared to $1.10 in Q1 2024[42] Shareholder Actions - The company repurchased $161 million of common stock, approximately 2.3 million shares, during Q1 2025[10] Guidance and Strategic Plans - The company maintained its 2025 non-GAAP diluted EPS guidance of $4.80 to $4.94, reflecting growth of 1% to 4% compared to 2024[19] - The company is focused on enhancing operational efficiency and customer experience as part of its refreshed BOLD+1 Strategic Plan for 2025 to 2027[4] Restructuring and Costs - The company recorded $25 million in restructuring costs in Q1 2025, aiming for annual savings of $75 million to $100 million by the end of 2025[9] - Restructuring costs for Q1 2025 were reported at $25 million pre-tax, up from $10 million in Q1 2024, with net restructuring costs of $17 million[43] - Acquisition intangible amortization for Q1 2025 was $43 million pre-tax, slightly down from $46 million in Q1 2024, with net amortization of $27 million[44] - Costs associated with shareholder advisory matters amounted to $8 million in Q1 2025[45] Cash Flow and Assets - Total current assets increased to $4,037 million as of March 29, 2025, compared to $3,983 million at the end of 2024[34] - Total assets grew to $10,480 million as of March 29, 2025, up from $10,218 million at the end of 2024[34] - Cash and cash equivalents at the end of Q1 2025 were $127 million, a slight increase from $122 million at the beginning of the period[37] - The company reported a net cash provided by operating activities of $37 million in Q1 2025, down from $197 million in Q1 2024[37] Sales and Services - Total global distribution and value-added services sales decreased by 0.7% to $2,676 million in Q1 2025 compared to $2,693 million in Q1 2024[39] Other Financial Metrics - Adjusted EBITDA for Q1 2025 was $259 million, compared to $255 million in Q1 2024[12] - Adjusted EBITDA for Q1 2025 was reported at $259 million, an increase from $255 million in Q1 2024[47] - The change in contingent consideration was recorded at $2 million in Q1 2025, compared to $15 million in Q1 2024[45] - The company received $20 million in insurance proceeds related to a cyber incident, with $15 million net of taxes recognized in Q1 2025[44]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Henry Schein, with a focus on how actual results compare to estimates, which could significantly impact stock price [1][2] Company Summary - Henry Schein is expected to report quarterly earnings of $1.11 per share, reflecting a year-over-year change of +0.9%, with revenues projected at $3.23 billion, up 1.8% from the previous year [3] - The consensus EPS estimate has been revised 1.02% lower in the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Henry Schein is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +1.89%, suggesting a likely earnings beat [10][11] - Historically, Henry Schein has beaten consensus EPS estimates three out of the last four quarters, indicating a positive trend [13] Industry Context - Cardinal Health, another player in the Zacks Medical - Dental Supplies industry, is expected to post earnings of $2.15 per share, with a year-over-year change of +3.4% and revenues of $55.03 billion, up 0.2% [17] - Cardinal Health's consensus EPS estimate has been revised 0.1% lower, but a higher Most Accurate Estimate has resulted in an Earnings ESP of 0.54%, suggesting a likely earnings beat [18]

It has been about a month since the last earnings report for Henry Schein (HSIC) . Shares have lost about 3.9% in that time frame, outperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Henry Schein due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since Then?It ...

Group 1 - The health care distributor Henry Schein (NASDAQ: HSIC) is viewed positively at its current price level, indicating a bullish outlook for the stock [1] - The analysis employs a technical approach focusing on price action, momentum, volume, and relative strength to support the bullish thesis for HSIC [1] - The article reflects the author's intent to build financial assets for retirement, highlighting a strategy that includes both long and short trading opportunities [1] Group 2 - The author expresses a commitment to developing winning trades and aims to learn from feedback in the comments section [1]

Group 1 - Henry Schein is identified as a notable company for investors, operating as a solutions provider in the healthcare sector [1] - The company is involved in generating cash flow, which is essential for value and growth prospects [1] Group 2 - Crude Value Insights offers an investment service focused on oil and natural gas, emphasizing cash flow analysis [2] - Subscribers have access to a stock model account and in-depth analyses of exploration and production firms [2]